Cyclo Therapeutics Inc (NQ: CYTH )

0.7000 -0.0200 (-2.78%)
Streaming Delayed Price Updated: 3:03 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,911
Open 0.7300
Bid (Size) 0.6900 (3)
Ask (Size) 0.7000 (26)
Prev. Close 0.7200
Today's Range 0.6900 - 0.7399
52wk Range 0.5946 - 2.115
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need 
From Rafael Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-57.83%
-57.83%
1 Month
-5.80%
-5.80%
3 Month
-41.18%
-41.18%
6 Month
-51.05%
-51.05%
1 Year
-52.38%
-52.38%

More News

Read More
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
From Pacira BioSciences
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
From Brodsky & Smith LLC
Via GlobeNewswire
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
From Cyclo Therapeutics
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
From Brodsky & Smith LLC
Via GlobeNewswire
This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
Via Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase
Via Benzinga
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
From Rafael Holdings, Inc.; Cyclo Therapeutics
Via GlobeNewswire
CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.